This week, reporters Neil Versel and Meghana Keshavan join Digital Health Editor Stephanie Baum to discuss the fallout of health IT costs from a Government Accountability Office report and hearings on Capitol Hill.
They will also explore some of issues around biotech investment coming out of the RESI conference Meghana covered this week as well as the massive IPO for Axovant Sciences advancing the development of an Alzheimer’s disease drug. It’s raised questions of whether we’re in the midst of a biotech bubble.
These topics, as well as other important news from the week that was in healthcare, are on deck for MedHeads at 4 pm Eastern today on Google+ and the embed below.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
MedHeads is MedCityNews.com’s weekly broadcast looking back at the week that was in the business of healthcare innovation. In these broadcasts, we’ll take the news seriously but won’t take ourselves too seriously.
Photo: RESI Conference
